Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report)’s share price traded down 8.1% during trading on Wednesday . The stock traded as low as $4.48 and last traded at $4.51. 13,783 shares changed hands during trading, a decline of 90% from the average session volume of 139,388 shares. The stock had previously closed at $4.91.
Alaunos Therapeutics Stock Down 8.1%
The business has a 50 day moving average price of $2.93 and a two-hundred day moving average price of $2.24.
Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.50) by $3.83. The business had revenue of $0.00 million during the quarter.
Alaunos Therapeutics Company Profile
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
Recommended Stories
- Five stocks we like better than Alaunos Therapeutics
- 3 Small Caps With Big Return Potential
- Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
- What does consumer price index measure?
- Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.